Showing 721-730 of 1484 results for "".
- Merz Aesthetics to Distribute AccuVein’s Visualization Systemhttps://practicaldermatology.com/news/merz-aesthetics-to-distribute-accuveins-visualization-system/2461829/Merz Aesthetics is now the sole authorized distributor of AccuVein’s vein visualization system in the U.S. aesthetics market. A limited initial AccuVein field pilot yielded positive results and significant expansion of both new customers and Merz Aesthetics portfolio adoption. Bas
- Fifth Piece of Art Added to Boehringer Ingelheim, FIT's DTech Unwearable Collectionhttps://practicaldermatology.com/news/fifth-piece-of-art-added-to-boehringer-ingelheim-fits-dtech-unwearable-collection/2461825/In partnership with the Fashion Institute of Technology's (FIT) DTech Lab and world-renowned designer, Bart Hess, Boehringer Ingelheim is introducing a fifth piece to The Unwearable Collection, an art collection that uses raw materials like paper and glass to uniquely illustrat
- FDA Clears Candela's Vbeam 595 nm Pulsed Dye Laser for the Treatment of Port Wine Stains and Hemangiomas in the Pediatric Populationhttps://practicaldermatology.com/news/fda-clears-vbeam-595-nm-pulsed-dye-laser-for-the-treatment-of-port-wine-stains-and-hemangiomas-in-the-pediatric-population/2461824/The U.S Food and Drug Administration has cleared candela’s Vbeam family of 595 nm wavelength pulsed dye lasers (PDL) to treat cutaneous capillary malformations, and infantile hemangiomas (IH)/congenital hemangiomas in the pediatric population (from birth – 21 years of age).
- A Sneak Peek in the AD Pike: Aslan’s Eblasakimab Blocks IL-13Rα1, Inhibits Activation of STAT6https://practicaldermatology.com/news/a-sneak-peek-in-the-ad-pike-aslans-eblasakimab-blocks-il-13ra1-inhibits-activation-of-stat6/2461821/Aslan's eblasakimab, a monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, is showing promise in atopic dermatitis (AD), according to part of a phase 1a, open-label, single ascending dose
- Topline Phase 2b Data: Amlitelimab Performs Well in ADhttps://practicaldermatology.com/news/topline-phase-2b-data-amlitelimab-performs-well-in-ad/2461820/Sanofi’s amlitelimab showed statistically significant improvements in signs and symptoms of moderate-to-severe atopic dermatitis in adults, according to topline Phase 2b data. Amlitelimab is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, a key immune re
- Welcome to Camp Dermhttps://practicaldermatology.com/news/welcome-to-camp-derm/2461816/As kids across the country got ready for summer camp, dermatologists flocked to Brooklyn, NY for their own version of summer camp: Neutrogena’s immersive SkinU Summer Camp. Instead of learning to swim, sliding down a zipline, or playing tennis like kids in camp ofte
- The Canadian Dermatology Association Announces 2023 Award Recipientshttps://practicaldermatology.com/news/the-canadian-dermatology-association-announces-2023-award-recipients/2461800/The Canadian Dermatology Association’s (CDA) 2023 Lifetime Achievement Award goes to Drs. James D. Walker and Peter Hull. Dr. Walker developed and constructed the first Mohs Surgical Unit to treat skin cancer at The Ottawa Hospital (TOH). He also helped raise more than $
- Health Canada Greenlights Sun Pharma’s Winlevi for Acnehttps://practicaldermatology.com/news/health-canada-greenlights-sun-pharmas-winlevi-for-acne/2461792/Health Canada has given its nod to Sun Pharma’s Winlevi (clascoterone cream 1%). Winlevi an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. It will be available in Canada this Fall. "
- Sirnaomics Gets FDA Go Ahead to Move STP705 Into Late-Stage Clinical Development for isSCChttps://practicaldermatology.com/news/sirnaomics-gets-fda-go-ahead-to-move-stp705-into-late-stage-clinical-development-for-isscc/2461788/Sirnaomics Ltd.’s STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) is moving into late-stage clinical development after encouraging Phase IIa and Phase IIb clinical results. These results were shared with the U.S. Food and Drug Administration (FDA) in an En
- FDA Nod for Avita Medical’s RECELL for Skin Repigmentation in Vitiligo Patientshttps://practicaldermatology.com/news/fda-nod-for-avita-medicals-recell-for-skin-repigmentation-in-vitiligo-patients/2461787/The U.S. Food and Drug Administration (FDA) has approved AVITA Medical, Inc.’s application for premarket approval (PMA) of its RECELL System for the treatment of vitiligo. RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic d